Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation"
Trial details
- Registry ID
- NCT04204252
- Drugs studied
- Alpha 1-Antitrypsin
TrialRedline tracks 1 clinical trial sponsored by Kamada, Ltd.: 1 Phase 3.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation"NCT04204252 | Alpha 1-Antitrypsin | Terminated | 2026-02-19Actual |
Names as written in the registry records.
NCT04204252 · Kamada, Ltd.
Before: Estimated. After: Actual.
Before: 220 participants (planned). After: 98 participants (actual).
Before: Estimated. After: Actual.
Before: Dec 2028. After: 19 Feb 2026.
Before: Recruiting. After: Terminated.